Previous 10 | Next 10 |
Harbour BioMed and Dana-Farber Cancer Institute Collaborate to Advance Novel Biotherapies for Cancer Treatment PR Newswire CAMBRIDGE, Mass. and ROTTERDAM, Netherlands and SUZHOU, China , June 15, 2021 /PRNewswire/ -- Harbour BioMed (HKEX: 0...
Mnemo Therapeutics Announces €75 million Series A to Accelerate Next Generation Integrated CAR-T and Epigenetic Targeting Platform Financing led by Casdin Capital, Sofinnova Partners - initial seed investor, and an undisclosed investor Mnemo delivers epigenetic antige...
Totient, a Viva Biotech Portfolio Company, has been Acquired by AbSci The combination of the Totient technology with AbSci's platform provides the framework and data to enable in silico targeted drug design, and ultimately achieve the goals of making the best medicines available...
Protagonist Therapeutics Announces Pricing of $115 Million Upsized Public Offering of Common Stock PR Newswire NEWARK, Calif., June 15, 2021 /PRNewswire/ -- Protagonist Therapeutics, Inc. (Nasdaq: PTGX), a clinical stage biopharmaceutical company, today announce...
FDA Approves StrataGraft for the Treatment of Adults with Thermal Burns PR Newswire SILVER SPRING, Md. , June 15, 2021 /PRNewswire/ -- Today, the U.S. Food and Drug Administration approved StrataGraft for the treatment of adult patients with thermal burns contain...
MOBILion Systems Launches MOBIE: The First SLIM-Based High-Resolution Ion Mobility (HRIM) Product to Accelerate Biotherapeutic Drug Development and Multiomic Biomarker Discovery PR Newswire CHADDS FORDS, Pa., June 15, 2021 /PRNewswire/ -- MOBILion Systems Inc . h...
AffyImmune Therapeutics Announces Addition of Dr. Jim Mulé to its Scientific Advisory Board PR Newswire NATICK, Mass. , June 15, 2021 /PRNewswire/ -- AffyImmune Therapeutics, Inc., a clinical stage biotechnology company developing safe, effective ways t...
Lightspeed Microscopy, Inc. raises $4M in Series A Financing Round with Plans to Revolutionize Pathology PR Newswire SEATTLE , June 15, 2021 /PRNewswire/ -- Lightspeed Microscopy, Inc., an end-to-end 3D pathology platform, announced today it has raised $4 milli...
BIO Digital Taiwan Day will be held on June 22 Post-COVID Future with Latest Disruptive Biotechnologies PR Newswire TAIPEI , June 15, 2021 /PRNewswire/ -- With COVID-19 dramatically changing the healthcare industry, organizations have been forced to adapt the...
Synlogic Presents Additional Preclinical Data on Therapeutic Candidates SYNB1934 for Phenylketonuria (PKU) and SYNB8802 for Enteric Hyperoxaluria at Synthetic Biology: Engineering, Evolution & Design (SEED) Conference Synlogic Presents Additional Preclinical Data on Therapeu...
News, Short Squeeze, Breakout and More Instantly...
Bio-Rad Laboratories Inc. Class A Company Name:
BIO Stock Symbol:
NYSE Market:
2024-05-09 12:34:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
Bio-Rad Laboratories, Inc. (NYSE: BIO and BIO.B), a global leader in life science research and clinical diagnostics products, today announced financial results for the first quarter ended March 31, 2024. First-quarter 2024 total net sales were $610.8 million, a decrease of 9.8 percent compare...
Aterian Inc. (ATER) is expected to report for Q1 2024 Dorman Products Inc. (DORM) is expected to report $0.82 for Q1 2024 Hillman Solutions Corp. (HLMN) is expected to report $0.08 for Q1 2024 Wake Forest Bancshares, Inc. (WAKE) is expected to report for quarter end 2024-03-31 Inn...